To report the independent prognostic impact of the new prostate cancer grade grouping system in a large external validation cohort of patients treated with radical prostatectomy.
Median follow-up was 52.7 months. The 5-year actuarial bRFS for biopsy grade-groups 1-5 were 94.2%, 89.2%, 73.1%, 63.1%, and 54.7%, respectively (p<0.0001). Similarly, the 5-year actuarial bRFS based on surgical grade groups was 96.1%, 93.0%, 74.0%, 64.4%, and 49.9% for grade groups 1-5, respectively (p<0.0001). The adjusted hazard ratios for bRFS relative to biopsy grade group 1 were 1.98, 4.20, 5.57, and 9.32 for groups 2, 3, 4, and 5, respectively (p<0.0001), and for surgical grade groups were 2. 09, 5.27, 5.86, and 10.42 (p<0.0001) . The five-grade group system had a higher prognostic discrimination compared to the commonly used 3-tier system (Gleason score 6 vs 7 vs 8-10).
In an independent surgical cohort, we have validated the prognostic benefit of the new prostate cancer grade grouping system with respect to bRFS, and demonstrated that the benefit is maintained after adjusting for important clinicopathologic variables. The greater predictive accuracy of the new system will improve risk stratification in the clinical setting and aid in patient counseling. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. 
